The New York-based firm is currently reviewing transaction terms for Destination XL Group, Standard BioTools, First Hawaiian, and Rallybio Corporation. Lawyers at Halper Sadeh are specifically looking into whether these agreements include provisions that stifle superior competing offers or offer outsized financial benefits to insiders that remain unavailable to the broader investor base.

For Standard BioTools, the merger with Treeline Biosciences leaves current shareholders with a 16% stake in the combined entity, while the First Hawaiian deal with TriCo Bancshares positions its investors to hold approximately 65%. Meanwhile, the Rallybio Corporation merger with Candid Therapeutics is set to leave its shareholders with a 3.65% interest. The firm aims to secure increased consideration or additional disclosures for those affected by these corporate moves. Investors seeking to challenge these transactions are encouraged to contact the firm, which operates on a contingent fee basis for such shareholder litigation matters.